Disc Medicine, Inc.
Moat Score — Disc Medicine, Inc.
Total Moat Score
6 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Disc Medicine's intangible value lies in its exclusive licenses to bitopertin (from Roche), DISC-0974 and DISC-0998 (from AbbVie), and DISC-3405 (from Mabwell), plus the clinical and regulatory know-how built from running the APOLLO, RALLY-MF, and RESTORE-PV trials -- but as licensed rather than wholly internally-discovered assets with no approved product yet, the underlying IP position is real but not yet proven or defensible at commercial scale. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage company with no commercial manufacturing or sales infrastructure, Disc Medicine has no cost advantage of any kind; it is spending heavily ($170.6 million in FY2025 R&D alone) with no revenue to offset it. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved products, Disc Medicine has no current pricing power; any future pricing power for bitopertin in EPP would depend on the still-unresolved question of how regulators and payers value PPIX reduction as a clinical benefit, following the FDA's February 2026 Complete Response Letter. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Disc Medicine's pipeline of small-molecule and antibody therapeutics has no network effect -- the value of bitopertin or DISC-0974 to one patient does not increase as more patients or physicians use it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Because none of Disc Medicine's candidates are approved, there is no prescriber or patient base yet established to create switching costs; any future stickiness would depend on first-mover advantage in indications like anemia of myelofibrosis where no approved on-label therapy currently exists. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Disc Medicine targets genuinely rare and specialty populations -- roughly 14,000 diagnosed EPP patients in the U.S. and a subset of the 25,000-patient U.S. myelofibrosis population with anemia -- small enough that a crowded field of well-funded rivals (Protagonist, Keros, BMS, GSK) is still racing for position rather than any single company having locked up the space. |